CO5140073A1 - Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina - Google Patents

Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina

Info

Publication number
CO5140073A1
CO5140073A1 CO99063348A CO99063348A CO5140073A1 CO 5140073 A1 CO5140073 A1 CO 5140073A1 CO 99063348 A CO99063348 A CO 99063348A CO 99063348 A CO99063348 A CO 99063348A CO 5140073 A1 CO5140073 A1 CO 5140073A1
Authority
CO
Colombia
Prior art keywords
group
compound
formula
alkyl
jpeg
Prior art date
Application number
CO99063348A
Other languages
English (en)
Inventor
Michael Stewart Hadley
Geoffrey Stemp
Christopher Norbert Johnson
Keong Vong Antonio Kuok
Gregor James Macdonald
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9821976.9A external-priority patent/GB9821976D0/en
Priority claimed from GBGB9824340.5A external-priority patent/GB9824340D0/en
Priority claimed from GBGB9910711.2A external-priority patent/GB9910711D0/en
Priority claimed from GBGB9918032.5A external-priority patent/GB9918032D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO5140073A1 publication Critical patent/CO5140073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I)<EMI FILE="99063348_1" ID="1" IMF=JPEG >en la que:R1 representa un sustituyente seleccionado entre: un átomo de hidrógeno o de halógeno; un grupo hidroxi, ciano, nitro, trifluorometilo, trifluorometoxi, trifluorometanosul- foniloxi, pentafluoroetilo, alquilo de C1-4, alcoxi de C1-4, aril-alcoxi de C1-4, alquil(C1-4)-tio, alcoxi de C1-4-alquilo de C1-4, cicloalquilo de C3-6-alcoxi de C1-4, alcanoilo de C1-4, alcoxi de C1-4-carbonilo, alquil(C1-4)sulfonilo, alquil(C1-4)sulfoniloxi, alquil(C1-4)sulfonilo-alquilo de C1-4, arilsulfonilo, arilsulfoniloxi, arilsulfonil-alquilo de C1-4, alquil(C1-4)sulfonamido, alquil(C1-4)amido, alquil (C1-4)sulfonamido-alquilo de C1-4, alquil (C1-4)amido-alquilo de C1-4, arilsulfonamido, arilcarboxamido, arilsulfonamido- alquilo de C1-4, arilcarboxamido-alquilo de C1-4, aroilo, aroil-alquilo de C1-4, o aril-alcanoilo de C1-4; un grupo R3OCO(CH2)p, R3CON(R4)(CH2)p, R3R4NCO(CH2)p ó R3R4NSO2(CH2)p, en cada una de cuyas fórmulas R3 y R4, independientemente, representa un átomo de hidrógeno o un grupo alquilo de C1-4 ó R3R4 forma parte de un anillo de azacicloalcano de C3-6 o (2-oxo)azacicloalcano de C3-6 y p representa cero o un número entero desde 1 a 4; o un grupo Ar3-Z, en el que Ar3 representa un anillo de fenilo opcionalmente sustituido o un anillo heterocíclico aromáticos de 5 o 6 miembros opcionalmente sustituido, y Z representa un enlace, O, S ó CH2; R2 representa un átomo de hidrógeno o un grupo alquilo de C1-4; q es 1 ó 2; A representa un grupo de la fórmula (a), (b) (c) o (d):-Ar -Ar1-Y-Ar2 <EMI FILE="99063348_2" ID="2" IMF=JPEG > (CH2)r-V-(CH2)sSr(a) (b) (c) (d) en las que: Ar representa un anillo de fenilo opcionalmente sustituido o un anillo heterocíclico aromático de 5 ó 6 miembros opcionalmente sustituido; o un sistema de anillos bicíclico opcionalmente sustituido; Ar1 y Ar2, cada uno independientemente, representan un anillo de fenilo opcionalmente sustituido o un anillo heterocíclico aromático de 5 ó 6 miembros opcionalmente sustituido; e Y representa un enlace, -NHCO-, -CONH-, -CH2- o -(CH2)mY1(CH2)n-, en cuyas fórmulas Y1 representa O, S, S02 o CO, y m y n representan cada uno cero ó 1, de tal modo que Ia suma de m+n es cero ó 1; con tal que cuando A representa un grupo de fórmula (a), cualquier sustituyente presente en Ar en posición orto respecto al resto de carboxamida es necesariamente un grupo hidrógeno o un grupo metoxi; r y s independientemente, representan un número entero desde cero a 3, de tal modo que la suma de r y s es igual a un número entero desde 1 a 4; V representa un enlace, 0 o S; y sus sales. - 2 -Un procedimiento de preparación de compuestos defórmula (I) cuyo procedimiento comprende:(a) hacer reaccionar un compuesto de fórmula (II)<EMI FILE="99063348_3" ID="3" IMF=JPEG >en la que R1, R2 y q son como se ha definido anteriormente, con un compuesto de fórmula (III):<EMI FILE="99063348_4" ID="4" IMF=JPEG >en la que A es como se ha definido anteriormente y X es un átomo de halógeno o el resto de un éster activado;(b) preparar un compuesto de fórmula (I) haciendo reaccionar un compuesto de fórmula (II) con un compuesto A-Br, o A-l, o A-OSO2CF3 en presencia de monóxido de carbono y un catalizador tal como bromuro de trans-bis-trifenilfosfinapaladio (II); (c) preparar un compuesto de fórmula (I) en la que R1 es Ar3-Z y Z es un enlace, haciendo reaccionar un compuesto de fórmula (IV);<EMI FILE="99063348_5" ID="5" IMF=JPEG >en la que R2 y A son como se ha definido anteriormente y un R1a representa un grupo W, en el que W es un átomo de halógeno o un grupo trifluorometilsulfoniloxi, o W es un grupo M seleccionado entre un derivado de boro, por ejemplo una función de ácido borónico B(OH)2 o una función metálica tal como trialquilestannilo, por ejemplo, SnBu3, haluro de cinc o haluro de magnesio, y cuando q es 2 el otro R1a es R1; con un compuesto Ar3-W1, en el que W1 es un átomo de halógeno o un grupo trifluorometilsulfoniloxi cuando W es un grupo M o W1 es un grupo M cuando W es un átomo de halógeno o un grupo trifluorometilsulfoniloxi;(d) preparar un compuesto de fórmula (I) en la que R1 es Ar3-Z y Z es O ó S, haciendo reaccionar un compuesto de fórmula (V):<EMI FILE="99063348_6" ID="6" IMF=JPEG >en la que R2 y A son como se ha definido anteriormente, y un R1b representa un grupo ZH, y cuando q es 2 el otro R1brepresenta R1; con un reactivo que sirve para introducir elgrupo Ar3;(e) preparar un compuesto de fórmula (I) en la que Y es un enlace, haciendo reaccionar un compuesto de fórmula (VI):<EMI FILE="99063348_7" ID="7" IMF=JPEG >en la que R1, R2, Ar1, W y q son como se ha definido anteriormente, con un compuesto Ar2-W1, en el que W1 es un átomo de halógeno o un grupo trifluorometilsulfoniloxi cuando W es un grupo M, o W1 es un grupo M cuando W es un átomo de halógeno o un grupo trifluorometilsulfoniloxi. (f) interconversión de un compuesto de fórmula (I) en un compuesto diferente de fórmula (I), por ejemplo, (i) alquilación de un compuesto (I) en el que R2 representa hidrógeno, (ii) conversión de un R1 desde alcoxi (por ejemplo, metoxi) a hidroxi, o (iii) conversión de R1 desde hidroxi a sulfoniloxi, por ejemplo, alquilsulfoniloxi o trifluorometanosulfoniloxi; (iv) conversión de un compuesto en el que Y representa S, en un compuesto en el que Y es S02 o (v) conversión de Y desde CO a CH2;(g) separación de los isómeros cis y trans de compuestos de fórmula (I) mediante métodos convencionales, por ejemplo, cromatografía o recristalización;y opcionalmente, después de esto, formar una sal de fórmula (I) .
CO99063348A 1998-10-08 1999-10-06 Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina CO5140073A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9821976.9A GB9821976D0 (en) 1998-10-08 1998-10-08 Compounds
GBGB9824340.5A GB9824340D0 (en) 1998-11-06 1998-11-06 Compounds
GBGB9910711.2A GB9910711D0 (en) 1999-05-07 1999-05-07 Compounds
GBGB9918032.5A GB9918032D0 (en) 1999-07-30 1999-07-30 Compounds

Publications (1)

Publication Number Publication Date
CO5140073A1 true CO5140073A1 (es) 2002-03-22

Family

ID=27451837

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99063348A CO5140073A1 (es) 1998-10-08 1999-10-06 Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina

Country Status (30)

Country Link
US (1) US6605607B1 (es)
EP (1) EP1119563B1 (es)
JP (1) JP2002527433A (es)
KR (1) KR20010085898A (es)
CN (1) CN1329609A (es)
AP (1) AP2001002114A0 (es)
AR (1) AR023681A1 (es)
AT (1) ATE316969T1 (es)
AU (1) AU761018B2 (es)
BG (1) BG105467A (es)
BR (1) BR9914370A (es)
CA (1) CA2346689A1 (es)
CO (1) CO5140073A1 (es)
CZ (1) CZ20011270A3 (es)
DE (1) DE69929704T2 (es)
EA (1) EA200100428A1 (es)
ES (1) ES2255311T3 (es)
HK (1) HK1038745A1 (es)
HU (1) HUP0104280A3 (es)
ID (1) ID28385A (es)
IL (1) IL142388A0 (es)
MA (1) MA26696A1 (es)
NO (1) NO20011745L (es)
NZ (1) NZ511018A (es)
OA (1) OA11663A (es)
PE (1) PE20001088A1 (es)
PL (1) PL347237A1 (es)
SK (1) SK4782001A3 (es)
TR (1) TR200101025T2 (es)
WO (1) WO2000021951A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
IL142388A0 (en) 1998-10-08 2002-03-10 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
CZ20031311A3 (cs) 2000-11-14 2004-04-14 Smithkline Beecham P. L. C. Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
WO2003062205A1 (en) * 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
JP2005517705A (ja) * 2002-02-13 2005-06-16 グラクソ　グループ　リミテッド ベンゼンスルホンアミド誘導体ならびにドーパミンｄ３およびｄ２受容体リガンドとしてのその使用
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
BR0317483A (pt) 2002-12-20 2005-11-16 Glaxo Group Ltd Derivados de benzodiazepina para o tratamento de desordens neurológicas
ES2624610T3 (es) 2003-04-11 2017-07-17 Ptc Therapeutics, Inc. Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
ATE529114T1 (de) 2003-12-18 2011-11-15 Abbott Gmbh & Co Kg Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
EP1725240A4 (en) * 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
JP2007529514A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
BRPI0617376A2 (pt) * 2005-10-13 2011-07-26 Morphochem Ag derivados de 5-quinolina tendo uma atividade antibacteriana
HUE036035T2 (hu) * 2013-12-13 2018-06-28 Pf Medicament Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra
CN106455571A (zh) 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
AR106530A1 (es) 2015-10-30 2018-01-24 Ptc Therapeutics Inc Métodos para tratar epilepsia
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
CN111433201B (zh) * 2017-12-21 2022-05-27 江苏恒瑞医药股份有限公司 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用
CN111801330B (zh) * 2018-01-26 2024-04-05 盐野义制药株式会社 具有多巴胺d3受体拮抗作用的稠环化合物
CN110498768A (zh) * 2018-05-17 2019-11-26 上海中泽医药科技有限公司 庚嗪类化合物及其在制备抗精神分裂症药物中的应用
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA792785B (en) * 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4220778A (en) 1978-10-30 1980-09-02 G. D. Searle & Co. 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
IL63918A0 (en) 1980-10-17 1981-12-31 Pennwalt Corp N-(amino(or hydroxy)phenethyl)-1,2,3,4-tetrahydroisoquinolines,their preparation and pharmaceutical compositions containing them
ZA816903B (en) 1980-10-17 1983-02-23 Pennwalt Corp N-(amino(or hydroxy)-1,2,3,4,-tetrahydroisoquinolines, precursors thereof, and methods of preparation
FR2618149B1 (fr) 1987-07-16 1989-09-22 Synthelabo Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
US5217977A (en) 1989-02-28 1993-06-08 Imperial Chemical Industries Plc Heterocyclic cycloalkanes
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5681956A (en) 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
CZ283038B6 (cs) 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
WO1993003025A1 (fr) 1991-08-09 1993-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thiophene
US5532240A (en) 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
KR930703327A (ko) 1991-12-26 1993-11-29 고야 다다시 축합형 티오펜 화합물 및 그의 의약용도
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
DE69310367T2 (de) 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate
AU4704593A (en) 1992-08-06 1994-03-03 Smithkline Beecham Plc 5-(2-oxyphenyl)-pyrrole derivatives as dopamine d3 receptor antagonists
US5294621A (en) 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
GB9305644D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
GB9307400D0 (en) 1993-04-08 1993-06-02 Smithkline Beecham Plc Compounds
FR2706895A1 (en) 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
AU7186994A (en) 1993-06-25 1995-01-17 Smithkline Beecham Plc Phenyrrole derivatives and their use as dopamine d3 antagonists
GB9315801D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
GB9315800D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
ATE231126T1 (de) 1993-08-12 2003-02-15 Astrazeneca Ab Amidin-derivate mit stickstoffoxid-synthease- aktivität
AU7665694A (en) 1993-09-21 1995-04-10 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
GB9320855D0 (en) 1993-10-09 1993-12-01 Smithkline Beecham Plc Compounds
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9325827D0 (en) 1993-12-17 1994-02-23 Smithkline Beecham Plc Compounds
GB9402197D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9403199D0 (en) 1994-02-19 1994-04-13 Smithkline Beecham Plc Compounds
WO1995029891A1 (fr) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de n-(3-pyrrolidinyl)benzamide
US5414010A (en) 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
GB9418912D0 (en) 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
PL319511A1 (en) 1994-10-05 1997-08-18 Glaxo Wellcome Inc Parenteral pharmaceutic compositions containing gf120918a
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5478934A (en) 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
GB9426071D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426090D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
JP3332929B2 (ja) 1995-02-15 2002-10-07 ニューロゲン コーポレイション ある種の架橋４−フェニル−２−アミノメチルイミダゾール：新しいドパミン受容体サブタイプ特異的リガンド
JPH11503116A (ja) 1995-03-27 1999-03-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 二環式アミン誘導体および抗精神病薬としてのそれらの使用
GB9512129D0 (en) 1995-06-15 1995-08-16 Smithkline Beecham Plc Compounds
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
FR2741074B1 (fr) 1995-11-09 1997-12-19 Adir Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
WO1997028166A1 (de) 1996-02-01 1997-08-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Thienochinoline
WO1997029079A1 (fr) 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5710274A (en) 1996-02-28 1998-01-20 Neurogen Corporation N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5763609A (en) 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703237A (en) 1996-04-18 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
CA2253927A1 (en) * 1996-05-11 1997-11-20 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
JP2000517301A (ja) * 1996-08-14 2000-12-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
WO1998007421A1 (fr) 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Composition medicinale
SK65499A3 (en) 1996-11-27 2001-05-10 Pfizer Apo b-secretion/mtp inhibitory amides
FR2761985B1 (fr) 1997-04-10 1999-05-21 Adir Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta[a] naphtalene et du 2,3-dihydro-cyclopenta[e]indene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7260398A (en) 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
WO1998050364A1 (en) * 1997-05-03 1998-11-12 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
IL142388A0 (en) 1998-10-08 2002-03-10 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9821977D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Also Published As

Publication number Publication date
KR20010085898A (ko) 2001-09-07
MA26696A1 (fr) 2004-12-20
ATE316969T1 (de) 2006-02-15
WO2000021951A1 (en) 2000-04-20
DE69929704T2 (de) 2006-07-20
HUP0104280A3 (en) 2002-07-29
IL142388A0 (en) 2002-03-10
PL347237A1 (en) 2002-03-25
PE20001088A1 (es) 2000-12-02
CN1329609A (zh) 2002-01-02
EP1119563A1 (en) 2001-08-01
ES2255311T3 (es) 2006-06-16
AP2001002114A0 (en) 2001-06-30
NO20011745D0 (no) 2001-04-06
AU1038100A (en) 2000-05-01
SK4782001A3 (en) 2001-11-06
JP2002527433A (ja) 2002-08-27
BG105467A (en) 2001-11-30
EP1119563B1 (en) 2006-02-01
CA2346689A1 (en) 2000-04-20
CZ20011270A3 (cs) 2001-09-12
NZ511018A (en) 2003-09-26
TR200101025T2 (tr) 2001-09-21
DE69929704D1 (de) 2006-04-13
BR9914370A (pt) 2001-11-27
NO20011745L (no) 2001-06-06
AU761018B2 (en) 2003-05-29
EA200100428A1 (ru) 2001-10-22
ID28385A (id) 2001-05-17
US6605607B1 (en) 2003-08-12
HK1038745A1 (zh) 2002-03-28
OA11663A (en) 2004-12-08
AR023681A1 (es) 2002-09-04
HUP0104280A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
CO5140073A1 (es) Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina
EA200401285A1 (ru) Меченные радиоактивными изотопами производные хинолина и хинолинона и их применение в качестве лигандов метаботропного глутаматного рецептора
CA2093132C (en) Process for the preparation of imidazo[4,5-c]quinolin-4-amines
CO5180557A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonan-4-carboxilatos y carboxamidas y sus composiciones farmaceuticas .
AR034792A1 (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
AR049401A1 (es) Aza-biciclononanos
ECSP056012A (es) Proceso para preparar derivados de feniltilamina
ME00108B (me) DE RIVATI DIOKSAN-2-ALKILKARBAMATA, POSTUPAK ZA NJIHOVO DOBIJANJ E l PRIMENA ISTIH U TERAPEUTICIMA
KR850008166A (ko) 인돌린 및 2-인돌리논 유도체의 제조방법
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
CN102408285B (zh) 一种甲苯衍生物的苄基碳氢直接胺化方法
DK1442006T3 (da) Fremstilling af amfetaminer fra phenylpropanolaminer
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
HUP0102657A2 (hu) Eljárás orto-alkilezett benzoesav-származékok, mint intermedierek és hatóanyagok előállítására
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
TW200517396A (en) Method for producing triarylsulfonium salt
Peng et al. Copper/Nickel‐Catalyzed Selective C–S/S–S Bond Formation Starting from O‐Alkyl Phenylcarbamothioates
RU2004139087A (ru) Замещенные арилбороновые кислоты, их получение и их предшественники
KR840005107A (ko) 피리미디온 및 그의 산부가염의 제조방법
AR245929A1 (es) Procedimiento para la preparacion de compuestos derivados de 3-fenoxibencilcarboxilato.
DK412587D0 (da) Quinolinderivater og disses fremstilling
DE60309346D1 (de) Halogensulfonylarylboronate
CO4790134A1 (es) Compuestos fungicidas a base de piridilaminopirimidinas y el proceso para prepararlas
Roshchin et al. Synthesis of 2-phenylindole N-derivatives under conditions of catalysis by palladium complexes